Best of April: Top 5 Insights In Outsourced Drug Development and Manufacturing

#1 - From Ally To Adversary: BIO's Swift Rebuke Of WuXi

The CEO of the Biotechnology Innovation Organization (BIO) spearheading expulsion of WuXi Apptec relied on WuXi Biologics as CEO of the biotech he founded. More on this and some breaking news on the U.S. government's accusations regarding WuXi, from Chief Editor Louis Garguilo.

#2 - Four Steps To Identifying The CDMO Proposal Worth Signing

The leap from sending your RFPs to choosing a CDMO partner requires the ability to think critically about the red flags and green flags of a given proposal. This article provides a breakdown of how to identify the CDMO proposal best suited for your project.

#3 - Shocking! Biotech Facilities Don't Maintain Themselves

Don't get trapped in the misconception that only biomanufacturing process systems need maintenance. Here are some real-life examples of facility maintenance programs gone wrong.

#4 - March 2024 – CDMO Opportunities And Threats Report

The report identifies CDMOs that might be impacted by key events affecting their clients, including company acquisitions, product acquisitions and licenses, product approvals, late clinical product terminations, and FDA rejections.

#5 - Impacts Of The Inflation Reduction Act (IRA)

Jesse Mendelsohn, a "pharmaceutical regulatory compliance and government pricing” guru, who manages a life sciences group of over 100 consultants, says currently the biggest disruptor to our industry in 2024 is the Inflation Reduction Act (IRA).